Navigation Links
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
Date:9/4/2007

the first half of 2008. NGX-4010 has been granted orphan status and has received fast track designation from the U.S. Food and Drug Administration (FDA) for HIV-DSP.

Regulatory and Commercialization Plans for NGX-4010

NeurogesX remains on track to complete the filing of a marketing authorization application (MAA) in 2007 for European regulatory approval of NGX-4010, under the European Medicines Agency's centralized filing procedure. The Company intends to seek approval in the European Union for a broad indication of peripheral neuropathic pain, which includes PHN, HIV-DSP and painful diabetic neuropathy (PDN), among others. The Company expects to submit an NDA with the FDA in the second half of 2008 for both PHN and HIV- DSP.

The Company has retained exclusive worldwide commercialization rights for NGX-4010 and intends to establish a focused specialty sales force in the United States to address its target market of pain centers and physicians who treat PHN and HIV-DSP. NeurogesX intends to enter into commercial partnerships for marketing and distribution outside the United States.

Conference Call and Webcast Information

A conference call to review the results of the C117 trial will begin at 11:30 a.m. EDT (8:30 a.m. PDT) on September 4, 2007 and will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer.

The conference call dial-in numbers are 1-877-407-0789 (USA) or 1-201-689-8562 (International). In addition, a dial-up replay of the conference call will be available beginning September 4, 2007 at 2:30 p.m. EDT (11:30 a.m. PDT) and ending on September 19, 2007. The replay telephone number is 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 254382.

A live web cast of the call will also be available from the Investor Relations section on the Company's web site at ht
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... SAN ANTONIO, Texas , Sept. 18, 2014  Casen ... vessels, skin and muscles to harden.  His case is one ... (GVM) in the world.  The only hospital in ... few in the world, offering treatment with the dual wave-length ... in San Antonio . Using a laser ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... companies. Competition for innovation, increasing clinical development costs, ... with the fast-changing environment are important factors driving ... and clinical trial costs continue to rise due ... Studies conducted by industry think tanks suggest ...
(Date:9/18/2014)... NORTHVALE, N.J. , Sept. 18, 2014 /PRNewswire/ ... Gianluca DeNovi , Ph.D. to its corporate ... DeNovi is an instructor at the Harvard Medical ... Bio-Medico of Rome.  He received his Masters degree ... and Control Systems from the University of Bologna. After ...
Breaking Medicine Technology:Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3
(Date:9/18/2014)... 2014 (HealthDay News) -- Daily supplements of selenium or ... development of age-related cataracts among men, a new study ... or both could help prevent cataracts. To investigate this ... Harvard Medical School in Boston, and his colleagues examined ... vitamin E. The trial was initially designed to study ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 TayganPoint ... announced today that President and co-founder John Cassimatis ... Innovation Award Winners for 2014, recognizing the region’s ... as an emerging executive of the year. , ... and life sciences that continue to shape the ...
(Date:9/18/2014)... 2014 Stealth Health Revolution co-founders, ... and Frank Davis, founder of Food for Health ... pleased to announce the new recipe book, "The ... nutrition-packed meals using Activz whole-food powders." The ... in the Stealth Health Revolution mission ...
(Date:9/18/2014)... can expect to pay higher employee contributions for their ... resource officers about the impact of the Patient Protection ... Obamacare) conducted by the Darla Moore School of Business ... , Patrick Wright, a professor in strategic human resource ... HR Officers. The survey is distributed to more than ...
(Date:9/18/2014)... to develop tools that would allow them to clearly ... a neuron fires to the resulting behavior in a ... working to develop a range of new tools to ... such tool that provides a new way of mapping ... collaboration between Viviana Gradinaru (BS ,05), assistant professor of ...
Breaking Medicine News(10 mins):Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3Health News:Sensing neuronal activity with light 2Health News:Sensing neuronal activity with light 3Health News:Sensing neuronal activity with light 4Health News:Sensing neuronal activity with light 5
... much about it. FlameEz.com is launched to provide the latest information ... of the most feared illnesses in middle and old age. ... ... Millions of Americans are affected by chronic inflammation without knowing much ...
... a ,must book-mark site,BETHESDA, Md., Jan. 14 The ... Foundation,s Web site -- www.cff.org -- the ... its "Best of the Web" review of 2008, the ... about cystic fibrosis. , , "This ...
... in French Hospital Market with More Than 130 ... ("Global Med" or the "Company") (OTC Bulletin Board: ... today announced that its subsidiary, Inlog, has licensed ... Serveur" in France) to nineteen additional hospitals during ...
... to Treat Diseases (HTDS) www.htdsmedical.com management ... agreement with Shenzhen Mellow Hope Pharm Industrial Co., ... biggest exporter of Biological Vaccines in China, and ... influenza, tetanus, diphtheria and other diseases; Blood based ...
... Quality Program ReviewsSEATTLE, Jan. 14 MetaStar, ... clinical guidelines and software from Milliman Care ... non-physician medical care reviews throughout the state. ... Milliman Care Guidelines (R) suite, MetaStar now ...
... insulin and oral human growth hormone formulations provide ... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ... Cobalamin(TM) oral drug delivery product development programs. The ... B12 oral uptake mechanism to facilitate oral absorption ...
Cached Medicine News:Health News:Control of Inflammation May Benefit Many of the Most Feared Illnesses in Middle and Old Age 2Health News:Control of Inflammation May Benefit Many of the Most Feared Illnesses in Middle and Old Age 3Health News:Cystic Fibrosis Foundation Web Site Rated 'Best of the Web' 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 2Health News:Global Med Technologies(R)' Inlog Subsidiary Licensed EdgeTrack to 62 French Hospitals in 2008, Including 19 Hospitals in Q4 2008 3Health News:Hard To Treat Diseases (HTDS) in Merger Talks with Mellow Hope, China 2Health News:Milliman Care Guidelines(R) Replaces Multiple Guideline Sets for Wisconsin QIO 2Health News:Milliman Care Guidelines(R) Replaces Multiple Guideline Sets for Wisconsin QIO 3Health News:Access Pharmaceuticals Provides an Update on Advances In Its Cobalamin(TM) Oral Drug Delivery Product Development 2Health News:Access Pharmaceuticals Provides an Update on Advances In Its Cobalamin(TM) Oral Drug Delivery Product Development 3
Cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, tip angled 30 to side wedge shaped inferior edge with blunt tip and front notch for engaging iris end opening, 19 gauge. For use in the right hand....
Irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip, 0.6 mm dual sideports, 20 gauge....
Irrigating nucleus chopper, semi-sharp, wedge shaped inferior edge with a pointed tip, dual sideports, 20 gauge. For Phakonit cataract surgery....
Medicine Products: